-
Product Insights
New![]()
Net Present Value Model: Autolus Therapeutics Plc’s AUTO-8
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Autolus Therapeutics Plc’s Obecabtagene autoleucel
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Applied Therapeutics Inc’s Gavorestat
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Resveratrol in Alzheimer’s Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Resveratrol in Alzheimer's DiseaseDrug Details: Resveratrol is under development for the treatment of Alzheimer's disease. It...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Bevacizumab Biosimilar in Metastatic Colorectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Bevacizumab Biosimilar in Metastatic Colorectal Cancer Drug Details:Bevacizumab biosimilar is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AUTO-8 in Relapsed Multiple Myeloma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.AUTO-8 in Relapsed Multiple Myeloma Drug Details:AUTO-8 is under development for the treatment of relapsed and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AUTO-8 in Refractory Multiple Myeloma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.AUTO-8 in Refractory Multiple Myeloma Drug Details:AUTO-8 is under development for the treatment of relapsed and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MRX-8 in Gram-Negative Bacterial Infections
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.MRX-8 in Gram-Negative Bacterial InfectionsDrug Details:MRX-8 is under development for the treatment of multi-drug resistant gram...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pidnarulex in Prostate Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pidnarulex in Prostate Cancer Drug Details: Pidnarulex is under development for the treatment of relapsed/refractory haematological...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AUTO-1/22 in Chronic Lymphocytic Leukemia (CLL)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.AUTO-1/22 in Chronic Lymphocytic Leukemia (CLL) Drug Details:AUTO-1NG is under development for the treatment of relapsed...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.